Ascletis Pharma (OTCMKTS:ASCLF) Shares Down 4% – Here’s What Happened

Ascletis Pharma Inc. (OTCMKTS:ASCLFGet Free Report) shares traded down 4% during trading on Friday . The company traded as low as $1.44 and last traded at $1.44. Approximately 100 shares were traded during trading, a decline of 96% from the average session volume of 2,831 shares. The stock had previously closed at $1.50.

Ascletis Pharma Stock Down 4.0%

The business has a 50 day simple moving average of $1.61 and a 200-day simple moving average of $1.79.

Ascletis Pharma Company Profile

(Get Free Report)

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Read More

Receive News & Ratings for Ascletis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascletis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.